Connect with our experts to learn more about bringing ODxET in your lab.

NEW! Webinar On Demand

ELCC 2024 Symposium: The Critical Role of Timely Genomic Profiling in NSCLC

The development of targeted therapies has led to a paradigm shift in the treatment of NSCLC. However, timely genomic profiling is the cornerstone of realizing the potential of precision oncology. 

In this recorded Industry Satellite Symposium from the European Lung Cancer Congress (ELCC) 2024, you will:

• Gain insights from multidisciplinary perspectives on biomarker testing in patients with NSCLC
• Discover the role of liquid biopsy when tumor tissue is limited

The time to informed treatment decisions is critical for oncology patients

The Oncomine Dx Express Test can deliver results in less than 24 hours, allowing the laboratory to combine the molecular biomarker results with the immunohistochemistry and provide one combined report to aid clinicians in making therapy decisions.

Learn more about the importance of timely availability of genomic profiling for oncology patients.

Even small biopsies should generate results

Oncomine Dx Express Test requires only 10 ng of DNA and RNA extracted from as little as two 5-micron FFPE slides, maximizing results from limited tissue and small biopsies. Plasma from liquid biopsy provides an additional sample type.

A true end-to-end solution, from specimen
to clinical report

The Genexus System workflow is easy to integrate NGS into any pathology laboratory. With automated library preparation, sequencing, analysis, and reporting involving as little as 20 minutes of hands-on time and a single IVD software it reduces laboratory staff burden, the potential for human errors, and alleviates the need for bioinformatics expertise.

Automation and ease of use are key to
enabling implementation of NGS workows
in every laboratory

Connect Genomic Alterations to Evidence

Oncomine Reporter Dx software helps users deliver a patient sample-specific summary of each biomarker matched with relevant therapies, guidelines, clinical trials and peer-reviewed literature.

• Relevant–matches the biomarker results to approved therapies, guidelines, clinical trials, and peer-reviewed publications
• Up-to-date–based on curated and monthly update information from multiple public sources.
• Flexible–one-page summary or a multi-page detailed report, templates available in several languages

Learn more about Oncomine Reporter Dx

Resources

Connect with our experts to learn more.

¹100% clinically relevant biomarkers = unique biomarkers that have an ESCAT level of IA, IB, or IC; majority = 86%, BRCA1/2 and MSI-H are not covered by the Oncomine Dx Express Test.
² Mosele F. et al. (2020) Ann Oncol 31:1491

For In Vitro Diagnostic Use. CE-IVD according to IVDD. Not available in all countries including the United States. The content provided herein may relate to products or workflows that have not been officially released or fully validated and is subject to change without notice. © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

Abbreviated Intended Use: The Oncomine Dx Express Test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology, the Ion Torrent Genexus Dx System to detect deletions, insertions, substitutions and copy number gain present in 42 genes and fusions in 18 genes from DNA and RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. Oncomine Dx Express Test also detects deletions, insertions, substitutions in 42 genes and fusions in 7 genes from cfTNA extracted from plasma samples. The Oncomine Dx Express Test is intended to provide clinically relevant tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines as an aid in therapy management of cancer patients with solid malignant neoplasms using FFPE samples and as an aid in therapy management of cancer patients with non-small cell lung cancer using plasma samples. It is not conclusive or prescriptive for labeled use of any specific therapeutic product.